Research Paper

Pancreatic Cancer detection via Galectin-1-targeted Thermoacoustic Imaging: validation in an in vivo heterozygosity model

Huan Qin¹,2✉, Baohua Qin¹,2#, Chang Yuan¹,2, Qun Chen¹,2 and Da Xing¹,2✉

¹. MOE Key Laboratory of Laser Life Science & Institute of Laser Life Science, College of Biophotonics, South China Normal University, Guangzhou 510631, China.
². Guangdong Provincial Key Laboratory of Laser Life Science, College of Biophotonics, South China Normal University, Guangzhou 510631, China.
#These authors contributed equally to this work.
✉Corresponding authors: Huan Qin, Ph.D., MOE Key Laboratory of Laser Life Science & Institute of Laser Life Science, South China Normal University, Guangzhou, 510631, China. E-mail: qinghuan@scnu.edu.cn. Da Xing, Ph.D., MOE Key Laboratory of Laser Life Science & Institute of Laser Life Science, South China Normal University, Guangzhou, 510631, China. Phone: +86-20-85211436-8301; Fax: +86-20-85211436; E-mail: xingda@scnu.edu.cn.

© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/).
See http://ivyspring.com/terms for full terms and conditions.

Received: 2020.03.13; Accepted: 2020.07.05; Published: 2020.07.14

Abstract

Purpose: To investigate the feasibility of microwave-induced thermoacoustic imaging (MTAI) in detecting small pancreatic tumors (<10 mm in diameter) and to complement the limitation of current clinical imaging methods.

Methods: A home-made MTAI system composed of a portable antenna and pulsed microwave generator was developed. The thermoacoustic nanoparticles were composed of the galectin-1 antibody for targeting pancreatic tumors and Fe₃O₄ nanoparticles as microwave absorbers (anti-Gal1-Fe₃O₄ nanoparticles). The microwave absorption properties of the nanoparticles were measured with a vector network analyzer and the resolving power of MTAI was investigated by imaging excised pancreatic tumors of different sizes (diameters of 1.0 mm, 3.1 mm, 5.0 mm, 7.2 mm). To simulate actual imaging scenarios, an in vivo heterozygosity model was constructed by covering the pancreatic tumors (~3 mm in diameter) in BALB/c nude mice with biologic tissue (~5 cm in depth). MTAI images of the heterozygosity model were acquired with/without the injection of the anti-Gal1-Fe₃O₄ nanoparticles and the thermoacoustic contrast from pancreatic tumors was evaluated with Student’s paired t test. The data were analyzed with analysis of variance and nonparametric statistics.

Results: Following intravenous infusion, anti-Gal1-Fe₃O₄ nanoparticles efficiently accumulated in the tumor. The MTAI contrast enhancement in pancreatic tumors with anti-Gal1-Fe₃O₄ nanoparticles was verified in vitro and in vivo. The pancreatic tumors were visible in nude mice examined with MTAI with a mean contrast enhancement ratio of 2.3 ± 0.15 (standard error of the mean) (P = .001) at 6 h post-injection of the nanoparticles. MTAI identified tiny pancreatic tumors in deep tissues with high fidelity.

Conclusion: MTAI offers deep imaging depth and high contrast when used with anti-Gal1-Fe₃O₄ nanoparticles. It can identify pancreatic tumors smaller than 5 mm, which is beyond the identification limit size (~10 mm) of other nondestructive clinical imaging methods. Thus, MTAI has great potential as an alternative imaging modality for early pancreatic cancer detection.

Key words: thermoacoustic imaging, small pancreatic tumors, nanoparticles

Introduction

Pancreatic cancer is one of the most lethal malignancies in humans with a five-year survival rate of less than 5% [1-2]. Earlier tumor detection can improve the 5-year survival rate—particularly in
subjects with tumors smaller than 10 mm in diameter [1-3]. Current clinical imaging methods, such as ultrasound imaging (USI), computed tomography (CT), and magnetic resonance imaging (MRI), each has advantages and disadvantages in pancreatic cancer detection.

USI is simple, economical, non-invasive, and repeatable, but it is of limited use in detecting pancreatic tumors smaller than 10 mm in diameter due to the small difference in acoustic impedance between tumors and background tissues [4]. CT does not identify tumors in 33% of pancreatic tumors <15 mm in diameter [5]. This low sensitivity for detecting tumors may be due to the size and the pathological characteristics of the tumor: lower tumor cellularity, more frequent intratumoral acinar tissues and islet cells, and less prominent tumor necrosis [6]. MRI can detect solid pancreatic neoplasms with extremely dense cellularity or extracellular fibrosis, especially when combined with a low apparent diffusion coefficient (ADC) in the tumor [7]. However, MRI is limited in definitively discriminating inflammatory and neoplastic solid lesions because of an overlap in ADC values between these two types [7]. Multi detector computed tomography (MDCT) scan combined with a contrast medium injection protocol avoids missing parts of the target, but this conservative approach could result in an undesired increase of the radiation dose to the normal pancreatic tissues surrounding the lesion [8]. Gadolinium-enhanced MR imaging has been shown to be equivalent or even superior to helical CT for imaging the pancreas [9]. Mangafodipir trisodium-enhanced MR imaging offers advantages in the detection of small pancreatic malignancies and of liver metastases but this technique and helical CT are equivocal for local staging of pancreatic cancer [10].

MTAI is a promising new imaging modality, combining the high contrast of microwaves and the high resolution of ultrasound. Thermoacoustic imaging (TA) signal generation is a result of microwave-induced thermal effects [11]. Small temperature rise can be produced when biological tissue is irradiated by a microwave pulse of adequate energy. The heated structure then thermally expands and contracts, thus producing a source of an acoustic pressure wave. MTAI detects the sound waves and reconstructs an image from the signals. This image represents the differences in microwave absorption inside the target. In recent years, efforts have been made to develop MTAI for the detection of breast, kidney, and prostate cancers and for brain imaging [11-15]. A typical MTAI system consists of a short-pulsed microwave source, a single transducer scanning subsystem, and an acoustic signal detection subsystem. Usually, the pulse width of a single microwave pulse is at hundreds of nanoseconds (ns), but recently less than 100 ns microwave pulses were tested [16-19]. The microwave source frequencies used for thermoacoustic imaging are 100, 108, and 434 MHz, and 1.2, 2.45, 6, and 9.4 GHz. Peak power of microwave source ranges from 5 kW to 350 kW [20-23].

MTAI is a potential alternative for early pancreatic cancer detection because microwave radiation has higher tissue penetration depth than light due to different contrast mechanisms. However, the difference of thermoacoustic response in the microwave-frequency between malignant tissues and healthy pancreatic tissues is low [24, Figure S1 of Supplement], limiting potential applications of MTAI in discriminating early-stage pancreatic tumors. One possible solution to this problem is to utilize exogenous contrast agents to increase the local dielectric loss in the tumors. For the past several decades, Fe3O4 nanoparticles with good biocompatibility and clinical availability have been studied as contrast agents in MRI. Fe3O4 nanoparticles also have high microwave absorption and may be advantageous in MTAI modalities [25].

Previous studies have shown that cancerous pancreatic tissue contains galectin-1 (Gal1) that is highly expressed in the cell membrane and stroma but rarely found in normal pancreatic tissues [26-38]. Gal1 overexpression in tumors is a marker of malignant tumor progression and is often related to cancer metastasis. Thus, Gal1 might have utility as a target for early detection of pancreatic tumors [28-31].

Currently, it is challenging to use MTAI systems in the clinical settings because of the use of a bulky antenna [36, 37], that allows very limited access to the tissue/organ sites for MTAI imaging. In this study, we developed a system with a portable antenna in which MTAI could be realized in the reflection-mode, allowing its use for imaging many tissues/organ sites (Figure 1A). Also, the size of the portable microwave generator was only 42 × 30 × 18 cm3, and could be conveniently utilized in an ambulance or bedside. The feasibility of MTAI early pancreatic cancer detection was investigated in a nude mouse heterozygosity model with pancreatic ductal adenocarcinoma (BxPC-3). We utilized Gal1 as a molecular target and DMSA-Fe3O4 nanoparticles as a probe for early stage pancreatic tumor detection with an MTAI schematically shown in Figure 1A. DMSA-Fe3O4 nanoparticles were labeled with a Gal1 antibody to construct anti-Gal1-Fe3O4 (Figure 1B). A vector network analyzer was used to measure the microwave absorption performance of anti-Gal1-Fe3O4 nanoparticles. The targeting ability of anti-Gal1-
Fe$_3$O$_4$ nanoparticles for pancreatic tumors was verified with fluorescence imaging; anti-Gal1-Fe$_3$O$_4$ nanoparticles could bind to pancreatic tumors and increase the local dielectric properties, boosting the microwave absorption in the tumors and, in turn, the MTAI signal. For in vitro experiments, we used excised pancreatic tumors (subcutaneous model, 1-7 mm in diameter) with inclusions containing agar at increasing depths, and compared the effect of anti-Gal1-Fe$_3$O$_4$ and DMSA-Fe$_3$O$_4$ nanoparticles on the MTAI signal. Tiny pancreatic tumors in deep tissue were identified by MTAI with high fidelity. Next, a murine model of pancreatic cancer (~3 mm in diameter tumors) was imaged with MTAI before and after intravenous injection of anti-Gal1-Fe$_3$O$_4$ nanoparticles. The results showed that MTAI could identify pancreatic tumors of 5 mm compared to the minimum diameter of ~10 mm achieved by other clinical nondestructive imaging methods (e.g., USI, CT, and MRI). Thus, MTAI has great potential for the detection of early stage pancreatic cancer.

**Materials and Methods**

**Synthesis and characterization of anti-Gal1-Fe$_3$O$_4$ nanoparticles**

The synthesis of anti-Gal1-Fe$_3$O$_4$ nanoparticles for pancreatic cancer imaging was performed following the procedure described in an earlier report [32]. Oleic acid (OA)-Coated Fe$_3$O$_4$ (20 mg, Shanghai So-Fe Biomedical Co., Ltd.) was dissolved in 2 mL methylbenzene, and di-mercapto-succinic acid (DMSA) (20 mg) was dissolved in 2 mL dimethyl sulfoxide (DMSO). These solutions were then mixed at room temperature under magnetic stirring for 24 h, then Ethyl acetate was added and stirred further for concentration and precipitation. For the formation of the DMSA-Fe$_3$O$_4$, it was collected by an electromagnet and adjusted to 1 mg/mL. 2.5 µL N-hydroxy succinimide (NHS) (10 mg/mL); 5 µL 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC) (10 mg/mL) were then dissolved in the solution of DMSA-Fe$_3$O$_4$ (DMSA-Fe$_3$O$_4$ nanoparticles, 1 mL), and sodium bicarbonate (NaHCO$_3$) was added.
to adjust the pH value to an appropriate range (8.0~8.4) suitable for amide reaction. Next, the mixture was stirred for 30 min at room temperature (25 °C) and 20 μL Gal1 polyclonal antibody (ab154351, Abcam, Cambridge, MA, USA) was added. The mixture was kept at 4 °C for 12 h. The final product was collected by centrifugation and stored at 4 °C. Anti-Gal1-Fe3O4 nanoparticles were characterized for particle size, zeta potential, ultraviolet spectrum, infrared spectrum, complex permittivity, and TA signal intensity. The sample (0.0001 mg/mL) was evenly distributed on the double-layer copper net, and was placed in the incubator for 24 h at 50 °C. The size of the nanoparticles was measured using a high-resolution transmission electron microscope (JEM-1400PLUS, HRTEM Company, Japan). The nanoparticles were diluted to ~0.1 mg/mL and slowly injected into a clean quartz cuvette, and characterized by dynamic light scattering (DLS, Malvern Zetasizer Nano-ZS 90, UK). The optical characteristics of the nanoparticles were investigated by UV-vis absorption spectra (Lambda-35 UV-vis spectrophotometer, PerkinElmer, MA, USA). Fourier transform infrared (FT-IR) spectra were recorded with a Thermo Nicolet 760 FTIR spectrometer (Madison, WI, USA) with a wavenumber range of 400 cm⁻¹ to 4000 cm⁻¹. The IR transmittance of the samples was averaged 20 times by a data acquisition card (50614, Topelec, China) at a sampling rate of 50 kHz.

**MTA1 system**

In this study, the repetition frequency of the home-made microwave generator (Pulse width: 550 ns; Peak power: 70 kW) was 20 Hz and the size was 42 × 30 × 18 cm³. The microwave generator consisted of a power supply and magnetron (10 kV rated voltage, 70 kW peak power). The power supply provided the magnetron with a high voltage of about 10 kV. The magnetron generated pulse microwave under the power supply excitation then transmitted it to the dipole antenna through the waveguide coaxial conversion system. The size of the dipole antenna output for microwave radiation was 5 × 5 cm², with an energy density in a single pulse per unit area of approximately (70 kW × 550 ns) / (5 × 5 cm²) = 1.54 mJ/cm².

An unfocused cylindrical needle ultrasonic transducer (Active-element diameter: 0.8 mm; Sensitivity: 10 nV/Pa; model: NCS-1; Manufacturing company: Institute of Acoustics, Chinese Academy of Sciences, China) with a central frequency of 1 MHz (80% bandwidth, ~6 dB) was used to detect thermo-acoustic signals. The acoustic pulse captured by the transducer was first amplified through a self-made voltage amplifier (Frequency Range: 30 kHz - 10 MHz; Noise Figure: 2.2 dB) with a gain of 27.8 dB. Then it was averaged 20 times by a data acquisition card (NDAQ-50614, Topelec, China) at a sampling rate of 50-M samples/s, and finally transferred to a personal computer for subsequent image processing. The limited-field-filtered back-projection algorithm was used for reconstructing the microwave absorber distribution. The projection data obtained from the ultrasonic detector was subjected to a one-dimensional Fourier transform and a convolution operation to obtain convolution filtered data in all directions, then back-projected in all directions and processed appropriately to obtain a tomographic image of the scanned object [36-38].

**Cell uptake and biodistribution of the nanoparticles**

Tumor cells were seeded on a glass-bottom petri dish at a density of 10⁴ cells/plate in 0.5 mL of culture medium for 12 h. Subsequently, Cy5.5/DMSA-Fe₃O₄ and Cy5.5/anti-Gal1-Fe₃O₄ nanoparticles (Fe concentration of 20 μM) were added to the culture medium. After incubation for 4 h, the cells were washed three times with phosphate-buffered saline (PBS), stained with MitoTracker Green for 30 min, washed three times with PBS, and analyzed by a Zeiss LSM 510 META laser confocal scanning microscope.
imaging system (Germany).

To examine whether anti-Gal1-Fe₃O₄ nanoparticle could enhance MTAI contrast of BxPC-3 cells, the cells were incubated with anti-Gal1-Fe₃O₄, DMSA-Fe₃O₄, and then washed three times with PBS. After centrifugation, the cells were injected into a capillary with a diameter of about 1 mm for MTAI.

The BxPC-3-bearing nude mice were randomly divided into two groups. Nude mice in groups 1 and 2 were intravenously injected with cy5.5/DMSA-Fe₃O₄ and cy5.5/anti-Gal1-Fe₃O₄ nanoparticles (Fe drug 2.5 mg/kg). Fluorescence imaging was performed at different time points (1, 3, 6, 12, and 24h post-injection) with an infrared imaging system (Odyssey L1-COR, USA).

**Imaging of the in vivo heterozygosity model**

Next, we sought to determine whether anti-Gal1-Fe₃O₄ could be used for tiny pancreatic tumor detection in vivo. In clinical practice, the preferred examination for detecting the pancreas is in a supine position. The abdominal ultrasound probe was placed at the xiphoid process for detection. The ultrasound signal penetrated abdominal muscles and then from the liver to the pancreas. A heterozygosity model was built to investigate clinical translation at deeper imaging depths in humans by adding biologic tissue with different thicknesses (chicken breast and liver) atop the pancreatic tumor skin of nude mice. The anti-Gal1-Fe₃O₄ nanoparticles were employed in MTAI for tiny pancreatic tumor detection with a dosage of 2.5 mg [Fe]/kg body weight.

The anesthetized nude mice were fixed horizontally in a tank filled with mineral oil. To prevent the asphyxia of nude mice, the head and forelimbs were always isolated from the oil by rubber tubes, and oxygen and isoflurane were continuously supplied. The non-focusing cylindrical ultrasonic transducer and dipole antenna fixed on the stepping motor system were immersed in mineral oil, and one-dimensional linear scanning was carried out at a distance of 1 cm in the skin of heterozygosity model to capture TA signal.

**Animal models**

The BXPC-3 cells in the logarithmic growth stage were harvested, centrifuged, and re-suspended in PBS. Subsequently, the cells were washed twice with PBS to remove serum. The cell concentration was adjusted to $1 \times 10^6$ / mL with PBS and 0.1 mL of cells were injected subcutaneously into the back of nude mice. The growth of pancreatic tumors was monitored and the diameter was recorded every day. Nude mice with a tumor diameter of 5mm were used in the subsequent experiments. All animal experiments were performed following a protocol approved by the Institutional Animal Care and Use Committee of South China Normal University. Four pancreatic tumor nude mice (BALB/c; provided by the Animal Experimental Center of Southern Medical University; weight range, 25.5-26.8 g) were initially anesthetized by using a mixture of bromethol (Nanjing AIBI Biotechnology Co., LTD, China) and tert-Amyl alcohol (Shenzhen Huarong Chemical Industry Trade Co., Ltd., China) at a dose of 240 mg/kg. TA and US images were collected before and after a 0.1-mL intravenous injection of DMSA-Fe₃O₄ and anti-Gal1-Fe₃O₄ nanoparticles with a dosage of 2.5 mg [Fe]/kg body weight. Throughout the experiment, full anesthesia was maintained with isoflurane gas, administered at 1 L/min of oxygen with 0.75% of isoflurane. Simultaneously, both heart rate and saturation of peripheral oxygen were monitored by using a pulse oximeter (AM-807, Medxing Medical, China). After imaging, animals were euthanized with an overdose of pentobarbital (Sleepaway; Huaxia Animal Health).

**Statistical analysis**

The Statistical analysis and graphic display of data were performed by using Origin software (version 8.50 for Windows; Origin Lab Corporation, Northampton, United States). All values were reported as mean ± standard error. P values were computed from a one-tailed distribution and were considered to indicate a significant difference if $<0.05$. Thermoacoustic signal enhancement was defined as the ratio between post- and pre-injection signal amplitudes from pancreatic tumor regions. Thermoacoustic contrast was defined as the ratio between signal amplitudes from pancreatic tumors and tissue background. ImageJ (1.5.2q, National Institutes of Health, USA) was used to compute the SNR of TA images. Oval tool is used to calculate the average gray value of the tumor area and the blank background. The linear SNR was calculated by the ratio of the average gray value of the tumor area to the average gray value of the blank background. All statistical analyses were performed by using software (Matlab 2016; MathWorks) with statistical tools (Statistics Toolbox; MathWorks).

**Results**

Galectin-1-targeted TA nanoprobe was composed of Gal1 antibody for targeting pancreatic tumors and a microwave absorber of Fe₃O₄ nanoparticles for enhancing TA signal. The physical size of the product was characterized by transmission electron microscopy (TEM) and dynamic light scattering (DLS). The anti-Gal1-Fe₃O₄ nanoparticles
exhibited uniform and spherical nanostructures with a diameter of around 120 nm. The hydrodynamic diameter was determined by DLS, indicating the average value of 142 nm with a polydispersity index (PDI) of 0.162 (Figure 2A). Anti-Gal1-Fe3O4 nanoparticles are negatively charged and existed in monodispersed form. The nanoparticles with the same charge repelled each other and were difficult to aggregate, ensuring the dispersion of nanoparticles in the solution. The zeta potential of anti-Gal1-Fe3O4 nanoparticles was -45.4 ± 3.25 mV in PBS, -47.5 ± 3.16 mV in Dulbecco’s Modified Eagle’s Medium (DMEM) and -48.8 ± 3.07 mV in DMEM with 10% fetal bovine serum (FBS), suggesting that the nanoparticles were stable in normal physiological solutions (Figure 2B) [38, 39]. To verify that the Gal1 antibody was successfully conjugated with the Fe3O4 nanoparticle, a Lambda-35 UV-vis spectrophotometer was used to test the optical absorption spectrum of nanoparticles. The results demonstrated that DMSA-Fe3O4 nanoparticles conjugated with the Gal1 antibody had a characteristic UV absorption peak of protein at 250-300 nm (Figure 2C). The Fourier transform infrared spectroscopy of DMSA-Fe3O4 Gal1 antibody and anti-Gal1-Fe3O4 further verified the formation of anti-Gal1-Fe3O4 (Figure 2D). There were characteristic peaks of DMSA (≡CH, -COOH, and -O) and Fe3O4 (-OH and Fe-O) on the surfaces of anti-Gal1-Fe3O4 and DMSA-Fe3O4 and there were amide I (C=O, 1690 cm⁻¹) and amide II bands (N-H, 1560 cm⁻¹) on the surface of anti-Gal1-Fe3O4, but not on the surface of DMSA-Fe3O4 [60-63]. The results provided evidence that Gal1 antibody had successfully conjugated with the Fe3O4 nanoparticle.

Figure 2. Characterization of anti-Gal1-Fe3O4 nanoparticles. A, Morphology of anti-Gal1-Fe3O4 nanoparticles was captured by TEM. The hydrodynamic diameter distribution was recorded for DMSA-Fe3O4 nanoparticles and anti-Gal1-Fe3O4 nanoparticles by DLS. B, Zeta potential for DMSA-Fe3O4 nanoparticles and anti-Gal1-Fe3O4 nanoparticles. C, UV Absorption spectra of DMSA-Fe3O4 nanoparticles (dashed line) and anti-Gal1-Fe3O4 nanoparticles (solid line). D, Fourier transform infrared spectroscopy of DMSA-Fe3O4 nanoparticles (black line), Galactin-1 antibody (blue line) and anti-Gal1-Fe3O4 nanoparticles (red line). E, Real (solid line) and imaginary (dashed line) parts of the permeability of DMSA-Fe3O4 nanoparticles. F, G, H, Real parts, imaginary parts, and tangent value of the complex relative permittivity of water, DMSA-Fe3O4 nanoparticles, and anti-Gal1-Fe3O4 nanoparticles aqueous suspension with mass concentrations of 1 mg/mL. I, MTAI signal intensity of DMSA-Fe3O4 and anti-Gal1-Fe3O4 nanoparticles with 1 mg/mL. The error bars represent triplicate samples and measurements (***P<0.001).
To explore the microwave absorption properties of DMSA-Fe₃O₄ and anti-Gal1-Fe₃O₄ nanoparticles, their relative dielectric constant and magnetic permeability were investigated with a vector network analyzer (AV3672B-S, the 41st Institute of CETC, China). Parameters related to microwave absorption including the permeability real part (µᵣ), imaginary part (µᵢ), and permittivity real part (εᵣ), imaginary part (εᵢ), and loss tangent (tan δ) values were obtained (Figure 2E-H). The εᵢ and tan δ for anti-Gal1-Fe₃O₄ showed higher values than deionized water, indicating a strong microwave absorption capacity. Anti-Gal1-Fe₃O₄ nanoparticles and unmodified Fe₃O₄ nanoparticles exhibited similar dielectric properties, indicating identical microwave absorption properties (Figure 2I). The TA signal intensity of anti-Gal1-Fe₃O₄ nanoparticles with 1 mg/mL was >17% higher than that of deionized water (P < 0.001). Unmodified Fe₃O₄ nanoparticles displayed TA signal intensity that was similar to anti-Gal1-Fe₃O₄ nanoparticles (P <0.001). The stability of anti-Gal1-Fe₃O₄ nanoparticles was confirmed, as displayed in Figure S3 (see supplementary material for details).

The excised pancreatic tumors with different sizes were used as phantoms (in Figure 3). We used a subcutaneous tumor model where BXPC-3 pancreatic tumor cells were inoculated in the back of male BALB/c nude mice. Tumors with different sizes were excised from mice with and without intravenous injection of anti-Gal1-Fe₃O₄ nanoparticles at the dose of 2.5 mg Fe/kg of body weight. Pancreatic tumors mimicking phantoms with diameters of 1.0 mm, 3.1 mm, 5.0 mm, and 7.2 mm were imaged to explore the resolving power of MTAI and the tumors with anti-Gal1-Fe₃O₄ are could be seen in the TA images. The average FWHM of the four 1D profiles were 1.2 mm ± 0.14, 3.1 mm ± 0.17, 5.2 mm ± 0.22, 7.2 mm ± 0.25, which were comparable to the sizes of the dissected pancreatic tumors as measured with a caliper (Figure 3A, B). These results demonstrated that anti-Gal1-Fe₃O₄ could enhance MTAI contrast in pancreatic tumor mimicking phantoms and that MTAI could distinguish phantoms less than 10 mm in diameter.
Next, the feasibility of MTAI for identifying tiny pancreatic tumors in deep tissue was investigated. The pancreas is generally about 4 centimeters deep from the skin. To simulate an actual imaging scenario, pancreatic tumor mimicking phantoms with diameters of 3.0 mm were covered with a layer of hybrid biological tissue. Figure 3C shows MTAI of pancreatic tumors at different depths of 1 cm, 3 cm, and 5 cm in the transverse plane. The TA signal from pancreatic tumor-mimicking phantoms with anti-Gal1-Fe3O4 nanoparticles was more prominent than that of pancreatic tumors without anti-Gal1-Fe3O4 nanoparticles. Although the imaging depth was increased, the average FWHM of the 1D profiles were 3.1 mm ± 0.21, 3.3 mm ± 0.18, 3.4 mm ± 0.19 at a depth of 1 cm, 3 cm, and 5 cm, respectively (Figure 3D), which were comparable to the caliper-measured sizes of the pancreatic tumor mimicking phantoms. Thus we have demonstrated that MTAI has the potential for imaging tiny pancreatic tumors in deep tissues with high fidelity.

Gal1 is highly expressed in pancreatic tumor cells and acts as a receptor for extracellular matrix proteins upon exposure to the Gal1 antibody [26-31]. To test whether anti-Gal1-Fe3O4 nanoparticles (Cy5.5-labelled) could specifically target pancreatic tumor cells (BxPC-3 cells), we incubated the nanoparticles with BxPC-3 cells overexpressing Gal1 on the surface; MCF-7 cells with low expression of Gal1 was used as a control. As an additional control, we also incubated BxPC-3 cells with Cy5.5-labelled DMSA-Fe3O4 nanoparticles (without the Gal1 antibody) and subjected all groups to the same treatment protocol. Using confocal microscopy, we detected fluorescence signal on the membranes of BxPC-3 cells incubated with anti-Gal1-Fe3O4 nanoparticles, while there was very minimal signal in the MCF-7 and BxPC-3 cells incubated with DMSA-Fe3O4 nanoparticles (Figure 4A, B). These results indicated that the anti-Gal1-Fe3O4 nanoparticles were specific to BxPC-3 cells and that targeting was mainly mediated by the interaction between Gal1 and Gal1 antibody.

To examine whether anti-Gal1-Fe3O4 nanoparticles could enhance MTAI contrast, BxPC-3 cells incubated with anti-Gal1-Fe3O4 nanoparticles and with saline were imaged. BxPC-3 cells incubated with DMSA-Fe3O4 nanoparticles served as an additional control. BxPC-3 cells incubated with anti-Gal1-Fe3O4 nanoparticles showed strong TA signal, while minimal TA signal was observed upon incubation of cells with saline or DMSA-Fe3O4 nanoparticles. The results indicated that anti-Gal1-Fe3O4 nanoparticles could specifically enhance MTAI contrast of BxPC-3 cells (Figure 4C, D).

We investigated the preferential accumulation of Cy5.5/anti-Gal1-Fe3O4 nanoparticles in tumor regions at various time points post-injection with an in vivo fluorescence imaging system. The tumors of Cy5.5/anti-Gal1-Fe3O4 nanoparticle-treated nude mice had much higher fluorescence intensities indicating better accumulation compared to mice treated with Cy5.5/DMSA-Fe3O4 nanoparticles at all time points (Figure 4E). The fluorescence intensity reached a maximum at 6 h post-injection for both nanoparticles. At this time, the signal-to-noise ratio (SNR) for Cy5.5/anti-Gal1-Fe3O4 nanoparticles-treated nude mice was 2.1-fold higher compared with Cy5.5/DMSA-Fe3O4 nanoparticles treatment (Figure 4F). Overall, these observations demonstrated the specific targeting properties of the anti-Gal1-Fe3O4 nanoparticles toward pancreatic tumors.

Next, we tested the ability of MTAI with anti-Gal1-Fe3O4 nanoparticles to identify tiny pancreatic tumors less than 5 mm in diameter within deep tissues. To simulate actual imaging, in vivo heterozygosity models were built by covering pancreatic tumors in nude mice with biologic tissues. Resolution experiments were performed to verify the imaging capability of the MTAI system in the simulated imaging scenarios. A 0.35 mm diameter copper wire was used as the microwave absorber to test the axial and lateral resolution of the MTAI system at different tissue depths. The axial resolution, which is determined by time-resolved ultrasonic detection, could be estimated with the following formula: $c/2f$, where $c$ is the speed of TA signal in oil (1500 m/s), and $f$ is the main frequency of ultrasonic transducer (1 MHz). The theoretical axial resolution for the transducer used in our experiments was 0.75 mm. The actual axial resolution of MTAI at depths of 0 cm, 1 cm, 3 cm, and 5 cm was 0.92 ± 0.07 mm, 0.96 ± 0.10 mm, 1.01 ± 0.32 mm, 1.07 ± 0.11 mm (P = 0.001) (Figure 5A), respectively. The lateral resolution was decreased along with the increase of imaging depth. The axial resolution of MTAI at four depths of 0 cm, 1 cm, 3 cm and 5 cm was measured to be 0.87 ± 0.06 mm, 0.98 ± 0.10 mm, 1.45 ± 0.13 mm, 1.71 ± 0.15 mm (standard error of the mean) (P = 0.001) (Figure 5B). Pancreatic tumors at three different depths [(thin human abdominal wall (0.5 cm-thick chicken breast + 0.5 cm-thick liver), normal human abdominal wall (1.5 cm-thick chicken breast + 1.5 cm-thick liver), and thick human abdominal wall (2.5 cm-thick chicken breast + 2.5 cm-thick liver)] were examined with MTAI before and after anti-Gal1-Fe3O4 nanoparticle injection through the tail vein with a dosage of 2.5 mg [Fe]/kg body weight. Pancreatic tumors at all four depths were clearly visible with SNR of 2.3 ± 0.15, 2.1 ± 0.09, 1.8 ± 0.14, and 1.9 ± 0.12 (P = 0.001) at 6 h after injection (Figure 5C, D). Notably,
The MTAI contrast of pancreatic tumors after injection of anti-Gal1-Fe3O4 nanoparticles increased by about 2.2-fold compared to pre-injection (standard deviation, 0.13) (Figure 5E). Generally, the dynamic range of image display was about 40-50 dB; however, the dynamic range of MTAI was less than 40 dB. During image post-processing, the TA signal was nonlinearly amplified to 50 dB to maximize differences in the display so the users could directly observe the image difference before and after the injection of nanoparticles. These results further demonstrated that the anti-Gal1-Fe3O4 nanoparticles could target the tumor site, and ultimately specifically enhanced the MTAI tumor contrast. Thus, MTAI could be a potential alternative for the detection of tiny pancreatic tumors.

Figure 4. Evaluation of the targeting ability of anti-Gal1-Fe3O4 nanoparticles. A, CLSM images of pancreatic cancer cells (BxPC-3) and breast cancer cells (MCF-7). B, Mean fluorescence intensity (MFI) in the interior cell region. C, MTAI, USI and overlay images of BxPC-3 in capillaries. D, MTAI contrast of BxPC-3 in capillaries. E, In vivo fluorescence imaging of a BxPC-3 murine model upon injection with Cy5.5/DMSA-Fe3O4 nanoparticles and Cy5.5/anti-Gal1-Fe3O4 nanoparticles at different time intervals. F, Fluorescence signal-to-noise ratio (SNR) in tumors upon injection with Cy5.5/DMSA-Fe3O4 nanoparticles and Cy5.5/anti-Gal1-Fe3O4 nanoparticles at different times (**P<0.01; ***P<0.001).
Figure 5. *In vivo* MTAI of pancreatic tumors in a heterozygosity model. A, Axial resolution of MTAI. B, Lateral resolution of MTAI. C, MTAI of pancreatic tumors covered with a layer of chicken breast and liver of different thicknesses on top of the mouse skin surface at increasing depths in vivo. D, Signal-to-noise ratio (SNR) in pancreatic tumors before and after injection with anti-Gal1-Fe3O4 at increasing depths. E, MTAI contrast of the pancreatic tumors. The error bars are based on triplicate samples. All MTAI and USI have the same scale bar of 1 cm (**P<0.01, ***P<0.001).

We investigated the *in vivo* behavior of anti-Gal1-Fe3O4 by measuring Fe levels in the tumors, various organs, urine and feces samples using inductively coupled plasma mass spectrometry.
Biodistribution data of anti-Gal1-Fe$_3$O$_4$ at different time intervals post-injection revealed relatively low accumulation of anti-Gal1-Fe$_3$O$_4$ in the heart and lung (Figure 6A). The accumulation of anti-Gal1-Fe$_3$O$_4$ in the liver and spleen was determined to be ~1.8 and ~1.2% ID at 24 h post-injection and further decreased to low levels after 3 days. High levels of the Ferrum element were observed in the tumor with about 4.8% ID at 24 h post-injection. This was likely due to the DMSA coating on the surface of Fe$_3$O$_4$, which could delay their macrophage clearance and escape from the reticuloendothelial systems (RES) during blood circulation and favor accumulation in the tumor by the dual targeting effect of the EPR and subsequent targeted binding with the Galectin-1 antigen on tumors. The feces and urine were also collected to study the possible clearance pathway of anti-Gal1-Fe$_3$O$_4$ (Figure 6B). High levels of Fe were detected in both urine and feces, indicating that anti-Gal1-Fe$_3$O$_4$ could be excreted through both renal and fecal routes, and very little retention of the remaining Fe-species was observed in the mouse body after 4 days. This observation was consistent with low levels of anti-Gal1-Fe$_3$O$_4$ in the liver, spleen, and kidney.
In vivo targeting efficiency of anti-Gal1-Fe₃O₄ after intravenous injection was evaluated by Prussian blue staining at different times. Within 12 h post-injection, due to the effective tumor accumulation and relatively less excretion, anti-Gal1-Fe₃O₄ was mainly distributed in the pancreatic tumor, and was rarely present in other organs such as heart, liver, spleen, lung, kidney and pancreas (Figure 6C), which was consistent with the results of ICP-MS.

Discussion

The gold standard for early detection of pancreatic cancer, Endoscopic Ultrasound (EUS), has a sensitivity of > 90% and is superior to the noninvasive MRI, USI and CT [40, 41]. However, EUS is an invasive imaging procedure and complications such as aspiration, bleeding, perforation of the digestive tract, and cardiovascular accidents may occur during the process [42-44]. In this context, MTAI of biological tissue has attracted considerable interest because it combines the spatial resolution of ultrasound and the contrast of microwave absorption [45, 46]. MTAI is non-invasive and has a lower risk compared with EUS. We demonstrated the feasibility of non-invasive in vivo detection of small pancreatic tumors in a heterozygous model using MTAI following anti-Gal1-Fe₃O₄ nanoparticle injection. Fe₃O₄ nanoparticles have been used extensively in humans with low toxicity [47, 58] and can be safely cleared from the body via the skin, bile, and liver [49-58]. Cell death was analyzed by MTT and FACS, showing that anti-Gal1-Fe₃O₄ had no significant effect on pancreatic tumor cells (BxPC-3) or macrophages (RAW 264.7) after 24 h even at concentrations as high as 0.5 mg/mL (Figure S4 of Supplement). The in vivo effect of anti-Gal1-Fe₃O₄ at this dose showed little long-term toxicity in nude mice (Figure 6). An efficient generation of TA signals requires thermal confinement. In our imaging system, the microwave pulse width was 550 ns with a repetition rate of 20 Hz, which met the thermal confinement condition. Heat diffusion was negligible and temperature increment was minimal. The microwave fluence on the skin was less than 10 mJ/cm², and could be increased by a factor of 12 while still conforming to the maximal permissible exposure allowed by the American National Standards Institute limits (20 mJ/cm²) [59]. TA signal strength and imaging depth separately depend on microwave absorption and fluence, and thus a higher concentration of contrast agents would likely enable better pancreatic cancer detection with even higher contrast values. Stronger microwave fluence would also enable tiny pancreatic cancer detection with even deeper imaging depths.

Although we conducted preliminary studies of the uptake dynamics of anti-Gal1-Fe₃O₄ nanoparticles in the pancreatic tumors of nude mice, further pharmacokinetic/pharmacodynamic studies are required including dose escalation studies. We performed initial feasibility studies, but better results might be achieved by tuning the nanoparticle parameters (e.g., shape, size). Additional studies are also needed to optimize microwave frequency.

The widely used microwave absorbers in TA imaging can be basically divided into two major categories according to their microwave loss mechanism. Nanomaterials such as carbon nanotubes, molybdenum disulfide and graphene nanoparticles are selected to be TA contrast agents based on their relatively large dielectric-loss, where the microwave absorption capability can be further improved by constructing charge disequilibrium sites such as defects on these nanomaterials [64, 65]. The second category microwave absorbers are hysteresis-loss-type nanomaterials and their microwave absorption capability can be achieved by optimizing structure and components to improve their hysteresis losses.

It is often argued that imaging may not be as effective for diagnosis as biomarkers, which are at the center stage for early detection [66-69]. However, imaging is always required for radiation therapy treatment planning. Given the thrust towards hypofractionation and high-dose therapy protocols, imaging becomes even more important. The imaging modality we have described in the current study may provide yet another effective tool in battling pancreatic cancer.

In summary, MTAI offers deep imaging depth and high contrast when used with anti-Gal1-Fe₃O₄ nanoparticles. MTAI can identify pancreatic tumors smaller than 5 mm in diameter, which is beyond the minimum size (~10 mm in diameter) achievable by other nondestructive clinical imaging methods. Thus, MTAI is an alternative for early pancreatic cancer detection.

Practical applications

The potential clinical implications of our study are important, as the ability to visualize abdominal pancreatic tumors in vivo permits the translation of this technology into the clinic. Image-guided biopsy of pancreatic lesions is now the standard of care. Although the use of a standard abdominal US is helpful in a subset of patients with pancreatic cancer, it is only helpful if the patient has a morphologically abnormal pancreatic mass. To the best of our knowledge, there are no reliable methods to identify pancreatic tumors noninvasively. This combination of noninvasive detection and needle biopsy would allow clinicians to diagnose pancreatic malignancies at an
early stage and direct appropriate treatment based on early detection.

**Abbreviations**

MTAI: Microwave-induced thermoacoustic imaging; USL: ultrasound imaging; CT: computed tomography; MRI: magnetic resonance imaging; Gal1: Galectin-1; OA: Oleic acid; FWHM: The average full widths at half maximum; DMSA: Dimercaptosuccinic acid; DMSO: Dimethyl sulfoxide; NHS: N-hydroxy succinimide; EDC: 1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride; NaHCO₃: Sodium Bicarbonate.

**Supplementary Material**

Supplementary figures and tables. http://www.thno.org/v10p9172s1.pdf

**Acknowledgments**

This research was supported by the National Natural Science Foundation of China (11604105, 61627827, 81630046, 91539127, 61705068), the National High Technology Research and Development Program of China (2015AA020901), the Science and Technology Planning Project of Guangdong Province (2019A151012052, 2015B020233016, 2016B020215003, the Ph.D. Start-up Fund of Natural Science Foundation of Guangdong Province (2017A030310363); the Scientific and Technological Planning Project of Guangzhou City (201805010002 and 201804010360).

**Competing Interests**

The authors have declared that no competing interest exists.

**References**

1. Lennon AM, Wolfgang CL, Canto MJ, Klein AP, Herman JM, Goggins M, et al. The early detection of pancreatic cancer: what will it take to diagnose and treat curable pancreatic neoplasm? Cancer Res. 2016; 74: 3381-9.
2. Zhou B, Xu J, Cheng Y, Gao J, Hu S, Wang L, et al. Early detection of pancreatic cancer: where are we now and where are we going? Int J Cancer. 2017; 41: 231-41.
3. Bailey P, Chang DK, Nones K, Johns AL, Patch A, Gingras M, et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature. 2016; 531: 47-52.
4. Krummala P, Jursaedi O, Agrawal B. Imaging of pancreatic cancer: an overview. J Gastrointest Oncol. 2011; 2: 168-74.
5. Prokesch RW, Chow LC, Beaulieu CF, Bammer R, Jeffrey RB. Isattenuating pancreatic adenocarcinoma at multi-detector row CT: secondary signs. Radiology. 2002; 224: 764-68.
6. Kim JH, Park SH, Yu ES, Kim M, Kim J, Byun JH, et al. Visually isoattenuating pathologic characteristics, and diagnosis at imaging examinations. Radiology. 2010; 257: 87-96.
7. Kikukawa M, Kamisawa T, Kuruma S, Chiba K, Kawaguchi S, Terada S, et al. Early diagnosis to improve the poor prognosis of pancreatic cancer. Cancers. 2018; 10: 48-57.
8. Mancoso P, Bettinardi V, Passoni P, Gusmini S, Cappio S, Gilardi MC, et al. Contrast enhanced 4D-CT imaging for target volume definition in pancreatic ductal adenocarcinoma. Radiother Oncol. 2008; 87: 339-42.
9. Nishiharu T, Yamashita Y, Abe Y, Mitsuzaki K, Tsuchigame T, Nakayama Y, et al. Local extension of pancreatic carcinoma: assessment with thin-section helical CT versus with breath-hold fast MR imaging-ROC analysis. Radiology. 1999; 212: 445-52.
10. Schima W, Fugger R, Schober E, Oertl C, Warnser P, Grabnerweger F, et al. Diagnosis and staging of pancreatic cancer: comparison of manadopiridil trisodium-enhanced MR imaging and contrast-enhanced helical hydro-CT. Am J Roentgenol. 2002: 179: 717-24.
11. Wang B, Zhao Z, Liu S, Nie Z, Liu Q, Mitigating acoustic heterogeneous effects in microwave-induced breast thermoacoustic tomography using multi-physical k-means clustering. Appl Phys Lett. 2017; 111: 223701-1-5.
12. Fu Y, Ji Z, Ding W, Ye F, Lou C. Thermoacoustic imaging over large field of view for three-dimensional breast tumor localization: a phantom study. Med Phys. 2014; 41: 110701.
13. Eckhart AT, Balmer RT, See WA, Patch SK. Ex vivo thermoacoustic imaging over large fields of view with 108 MHz irradiation. IEEE Trans Bio Eng. 2011; 58: 2238-46.
14. Prokesch RW, Chow LC, Beaulieu CF, Bammer R, Jeffrey RB. Isattenuating pancreatic adenocarcinoma at multi-detector row CT: secondary signs. Med Phys. 2010; 37: 4602-7.
15. Lou C, Yang S, Ji Z, Chen Q, Xing D. Ultrashort microwave-induced thermoacoustic imaging: a breakthrough in excitation efficiency and spatial resolution. Phys. Rev. Lett. 2012: 109: 218101.1-5.
16. Path S K, Hull D, Thomas M, Griep SK, Jacobsohn K, See WA. Thermoacoustic contrast of prostate cancer due to heating by very high frequency irradiation. Phys Med Biol. 2015; 60: 689-708.
17. Razansky D, Kellnerberger S, Ntziachristos V. Near-field radiofrequency thermoacoustic tomography with impulse excitation. Med phys. 2010; 37: 645-7.
38. Gazori T, Khoshayand MR, Azizi E, Yazdizade P, Nomani A, Haririan I. Evaluation of alginate/chitosan nanoparticles as antisense delivery vector: formulation, optimization and in vitro characterization. Carbohydr Polym. 2009; 79: 590-606.

39. Pooja D, Panyaram S, Kulhari H, Ranchamalla SS, Sistla R. Xanthan gum stabilized gold nanoparticles: Characterization, biocompatibility, stability and cytotoxicity. Carbohydr Polym. 2014; 110: 1-9.

40. Catanzaro A, Richardson S, Veloso H, Isenberg G, Wong RCK, Sivak MV, et al. Long-term follow-up of patients with clinically indeterminate suspicion of pancreatic cancer and normal EUS. Gastrointest Endosc. 2004; 58: 836-40.

41. Hunt GC, Faigel DO. Assessment of EUS for diagnosing, staging, and determining resectability of pancreatic cancer: a review. Gastrointest Endosc. 2002; 55: 232-7.

42. Ahmad NA, Lewis JD, Ginsberg CG, Rosato EF, Morris JB, Kochman ML. EUS in preoperative staging of pancreatic cancer. Gastrointest Endosc. 2000; 52: 463-8.

43. Helmasteder L, Riemann JF. Pancreatic cancer-EUS and early diagnosis. Langenbecks Arch. Surg. 2008; 393: 923-7.

44. Kasogi SK, Rivera JN, Gesnser RC, Chang S, Dayton PA. Early assessment of tumor response to radiation therapy using high-resolution quantitative microvascular ultrasound imaging. Theranostics. 2018; 8: 156-68.

45. Wang X, Bauer DR, Vollin JL, Manzi DG, Witte RS, Xin H. Impact of microwave pulses on thermoacoustic imaging applications. IEEE Antennas Wirel Propag Lett. 2013; 11: 1634-7.

46. Yang Y, Yanzhong LI, Liu G, Xia H, Xia Z. Experimental study of magnetically mediated thermoacoustic imaging. High Volt Eng. 2017; 43: 2518-23.

47. Koo OMY, Rubinstein I, Oryukseo H. Role of nanotechnology in targeted drug delivery and imaging: a concise review. Nanomed-Nanotechnol Biol Med. 2005; 1: 193-212.

48. Moghimi SM, Szebeni J. Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog Lipid Res. 2003; 42: 465-78.

49. Li S, Huang L. Pharmacokinetics and biodistribution of nanoparticles. Mol Pharm. 2008; 5: 496-504.

50. Ruiz A, Hernandez Y, Cabal C, Gonzalez E, Veintemillas-Verdaguer S, Martinez E, et al. Biodistribution and pharmacokinetics of uniform magnetite nanoparticles chemically modified with polyethylene glycol. Nanoscale. 2013; 5: 11400-8.

51. Kolosnjaj-Tabi J, Lartigue L, Javed Y, Luciani N, Pellegrino T, Wilhelm C, et al. Biotransformations of magnetic nanoparticles in the body. Nano Today. 2016; 11: 280-4.

52. Wilhelms S, Tavares AJ, Dai Q, Ohta S, Audet J, Dvorak HF, et al. Analysis of nanoparticle delivery to tumours. Nat Rev Mater. 2016; 1: 16034.

53. Petrov RA, Desimone JM. Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov. 2010; 9: 615-27.

54. Gu L, Fang RH, Sailor MJ, Park J. In vivo clearance and toxicity of monodisperse iron oxide nanocrystals. ACS Nano. 2012; 6; 4947-54.

55. Xu H, Cheng L, Wang C, Ma X, Li Y, Liu Z. Polymer encapsulated upconversion nanoparticle/iron oxide nanocomposites for multimodal imaging and magnetic targeted drug delivery. Biomaterials. 2011; 32: 9544-73.

56. Corot C, Robert P, Iede J, Port M. Recent advances in iron oxide nanocrystal technology for medical imaging. Adv Drug Deliv Rev. 2006; 58: 1471-504.

57. Brileysæbo K, Bjornerud A, Grant D, Ahlstrom H, Berg H, Kindberg GM. Hepatic cellular distribution and degradation of iron oxide nanoparticles following single intravenous injection in rats: implications for magnetic resonance imaging. Cell Tissue Res. 2004; 316: 315-23.

58. Armani H, Khandhar AP, Liggitt D, Krishnan KM. In vivo delivery, pharmacokinetics, biodistribution and toxicity of iron oxide nanoparticles. Chem Soc Rev. 2015; 44: 8576-607.

59. IEEE 2014 IEEE standard for military workplaces—force health protection regarding personnel exposure to electric, magnetic and electromagnetic fields, 0 Hz to 300 GHz. IEEE Std C95.1-2345-2014 (New York: IEEE-SA Standards Board).

60. Navin CV, Krishna KS, Bovenkamplangois GL, Miller JT, Chattopadhyay S, Shibata T, et al. Investigation of the synthesis and characterization of platinum-DMSA nanoparticles using millifluidic chip reactor. Chem Eng J. 2015; 281: 81-6.

61. Saber O, Mohamed NH, Aljaafari A. Synthesis of magnetic nanoparticles and nanoshells for oil spill removal. Nanosci Nanotechnol Asia. 2015; 5: 32-43.

62. Zhang S, Zhai Y, Zhang Z. Preparation and properties of magnetic sensitive nanosheets for oil spill removal. Nanosci Nanotechnol Asia. 2015; 5: 32-43.

63. Yuan C, Qin B, Qin H, Xing D. Increasing dielectric loss of a graphene oxide nanoparticle to enhance the microwave thermoacoustic imaging contrast of breast tumor. Nanoscale. 2019; 11: 22222-9.

64. Yoon YI, Kwon YS, Cho HS, Heo SH, Park KS, Park SG, et al. Ultrasound-mediated gene and drug delivery using a microbubble-liposome particle system. Theranostics. 2014; 4: 1133-44.